The majority of GBA mutations do not affect the catalytic site of glucosylceramidase, and so other mechanisms must account for loss of enzyme activity in Parkinson’s disease and Gaucher disease (Hruska et al., 2008). This evidence concerns the gene GBA1 and Parkinson disease.